Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Lupus 2012: New targets, new approaches

Meeting abstract

SLE risk alleles and cell development and activation

SJ Kim*, N Manjarrez Orduno, PK Gregersen and B Diamond

  • * Corresponding author: SJ Kim

Author affiliations

Feinstein Institute for Medical Research, Manhasset NY 11030, USA

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2012, 14(Suppl 3):A8  doi:10.1186/ar3942

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S3/A8


Published:27 September 2012

© 2012 Kim et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Meeting abstract

Understanding the functionality of lupus susceptibility alleles may best be done using cells of healthy individuals harboring one or two copies of the susceptibility allele. With this approach, confounding variables introduced by disease and medication are avoided. We have studied the SLE susceptibility allele of Blimp-1 in dendritic cells and Csk in B cells. The Blimp-1 risk allele exhibits low expression and leads to an increased secretion of proinflammatory cytokines. The Csk risk allele leads to enhanced expression and an increased response to B-cell receptor signaling. These effects of the risk alleles on activated or resting cells, respectively, provide insight into disease pathogenesis.